382 related articles for article (PubMed ID: 7693955)
1. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
[TBL] [Abstract][Full Text] [Related]
2. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Bajorin DF; Bosl GJ; Lyn P; Vlamis V
J Clin Oncol; 1997 Jul; 15(7):2546-52. PubMed ID: 9215823
[TBL] [Abstract][Full Text] [Related]
3. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity.
Motzer RJ; Mazumdar M; Bosl GJ; Bajorin DF; Amsterdam A; Vlamis V
J Clin Oncol; 1996 Apr; 14(4):1098-105. PubMed ID: 8648363
[TBL] [Abstract][Full Text] [Related]
4. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.
Broun ER; Nichols CR; Turns M; Williams SD; Loehrer PJ; Roth BJ; Lazarus HM; Einhorn LH
Cancer; 1994 Mar; 73(6):1716-20. PubMed ID: 7512438
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999).
Morris MJ; Bosl GJ
Int J Cancer; 1999 Dec; 83(6):834-8. PubMed ID: 10597205
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
7. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.
Broun ER; Nichols CR; Gize G; Cornetta K; Hromas RA; Schacht B; Einhorn LH
Cancer; 1997 Apr; 79(8):1605-10. PubMed ID: 9118046
[TBL] [Abstract][Full Text] [Related]
8. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
9. [Germ cell tumor].
Kasai M; Kiyama Y
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1749-55. PubMed ID: 7574805
[TBL] [Abstract][Full Text] [Related]
10. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
11. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
12. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
Mencel PJ; Motzer RJ; Mazumdar M; Vlamis V; Bajorin DF; Bosl GJ
J Clin Oncol; 1994 Jan; 12(1):120-6. PubMed ID: 7505805
[TBL] [Abstract][Full Text] [Related]
13. [High-dose chemotherapy with peripheral blood stem cell autotransplantation for patients with poor-risk testicular germ cell tumors--pilot study of the Japan Blood Cell Transplantation Study Group].
Nakagawa S; Miki T; Akaza H; Ozono S; Okano T; Sonoda Y; Tsukamoto T; Terachi T; Naito K; Naito S; Nishiyama T; Nonomura N; Hara I; Hoshi S; Yoshida O
Hinyokika Kiyo; 1999 Nov; 45(11):805-9. PubMed ID: 10637748
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
16. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
[TBL] [Abstract][Full Text] [Related]
17. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.
Bosl GJ; Geller NL; Vogelzang NJ; Carey R; Auman J; Whitmore WF; Herr H; Morse M; Sogani P; Chan E
J Clin Oncol; 1987 Mar; 5(3):436-40. PubMed ID: 2434627
[TBL] [Abstract][Full Text] [Related]
18. Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors.
Pico JL; Ibrahim A; Castagna L; Bourhis JH; Chazard M; Maraninchi D; Droz JP
Oncology; 1993 Nov; 50 Suppl 2():47-52. PubMed ID: 8233302
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated.
Motzer RJ; Gulati SC; Crown JP; Weisen S; Doherty M; Herr H; Fair W; Sheinfeld J; Sogani P; Russo P
Cancer; 1992 Jan; 69(2):550-6. PubMed ID: 1309436
[TBL] [Abstract][Full Text] [Related]
20. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
Nichols CR; Tricot G; Williams SD; van Besien K; Loehrer PJ; Roth BJ; Akard L; Hoffman R; Goulet R; Wolff SN
J Clin Oncol; 1989 Jul; 7(7):932-9. PubMed ID: 2544687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
